Derma Sciences Inc. (DSCI) Upgraded to Buy at Zacks Investment Research
Derma Sciences Inc. (NASDAQ:DSCI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage currently has a $5.25 target price on the stock. Zacks Investment Research’s target price points to a potential upside of 12.90% from the company’s current price.
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet upgraded Derma Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $7.25.
Derma Sciences (NASDAQ:DSCI) traded up 1.09% on Tuesday, hitting $4.65. The company had a trading volume of 32,599 shares. The stock’s market cap is $131.62 million. Derma Sciences has a 12-month low of $2.85 and a 12-month high of $5.99. The firm’s 50 day moving average price is $4.68 and its 200 day moving average price is $4.24.
Derma Sciences (NASDAQ:DSCI) last released its earnings results on Tuesday, August 9th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.16. The company earned $22.20 million during the quarter, compared to analyst estimates of $22.40 million. Derma Sciences had a negative return on equity of 11.74% and a negative net margin of 21.19%. Equities analysts predict that Derma Sciences will post ($0.04) earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in DSCI. Jacobs Levy Equity Management Inc. raised its stake in shares of Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock valued at $364,000 after buying an additional 73,911 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Derma Sciences by 2.5% in the first quarter. Franklin Resources Inc. now owns 2,684,500 shares of the company’s stock valued at $8,322,000 after buying an additional 65,192 shares in the last quarter. Emerald Acquisition Ltd. purchased a new stake in shares of Derma Sciences during the second quarter valued at about $202,000. Granahan Investment Management Inc. MA raised its stake in shares of Derma Sciences by 5.1% in the first quarter. Granahan Investment Management Inc. MA now owns 1,028,460 shares of the company’s stock valued at $3,188,000 after buying an additional 50,142 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock valued at $3,163,000 after buying an additional 8,376 shares in the last quarter. Institutional investors and hedge funds own 62.44% of the company’s stock.
About Derma Sciences
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
Receive News & Stock Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related stocks with our FREE daily email newsletter.